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Abstract While street drugs appear unlikely to alter the
metabolism of antiretroviral (ARV) medications, several
ARVs may induce or inhibit metabolism of various street
drugs. However, research on these interactions is limited.
Case reports have documented life-threatening overdoses of
ecstasy and gamma-hydroxybutyrate after starting ritonavir,
an ARV that inhibits several metabolic enzymes. For opioid
addiction, methadone or buprenorphine are the treatments
of choice. Because a number of ARVs decrease or increase
methadone levels, patients should be monitored for meth-
adone withdrawal or toxicity when they start or stop ARVs.
Most ARVs do not cause buprenorphine withdrawal or
toxicity, even if they alter buprenorphine levels, with rare
exceptions to date including atazanavir/ritonavir associated
with significant increases in buprenorphine and adverse
events related to sedation and mental status changes in
some cases. There are newer medications yet to be studied
with methadone or buprenorphine. Further, there are many
frequently used medications in treatment of complications
of HIV disease that have not been studied. There is need for
continuing research to define these drug interactions and
their clinical significance.
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Introduction
Many people with HIV use street drugs [1]. People who use
street drugs (eg, heroin, cocaine, methamphetamine, club
drugs) are at high risk for contracting HIV, hepatitis C, and
other infections from used needles, syringes, or pipes, or
from unprotected sex with high-risk partners, group sexual
encounters, or exchanging sex for drugs for sex. Drug use
also predicts progression of HIV disease, even when
controlling for associated risk factors such as medication
nonadherence [2]. As a result, many drug users with HIV
will require treatment with antiretroviral medications (ARVs).
Thus, it is essential for HIV clinicians to know their patients’
street drug use, and to convey to them how their reactions to
street drugs may change when they start or stop ARVs.
Clinicians also need to know how street drug use may affect
patients’ response to ARVs, so that they can advise patients to
stop using certain drugs, assist the patient with obtaining
substance abuse treatment, or can select effective ARVs that
do not interact with the specific street drugs used.
Many street drug users with HIV have developed
addictions requiring treatment with medications. Many
heroin-addicted patients need long-term maintenance with
opioid therapy such as methadone or buprenorphine to
prevent relapse, illness, and early death [3]. Medications for
cocaine and methamphetamine addiction are in develop-
ment. In this article, we review existing literature on
clinically relevant drug interactions of ARVs with street
drugs and opioids used in the treatment of opioid addiction.
ARV Metabolism
Adverse drug interactions can occur through several
mechanisms, either pharmacodynamic (between drugs with
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alter or are substrates of the same metabolic enzyme[s] or
other drug disposition pathways). Most pharmacokinetic
interactions occur when a drug increases or decreases
metabolism of other drugs in the liver (cytochrome P450
[CYP] enzymes or glucuronidation). Other causes of
pharmacokinetic interactions occur with changes in drug
transport by P-glycoprotein, or in drug absorption.
Most ARVs used in the treatment of HIV are metabo-
lized by the CYP450 enzymes [4], as are most drugs of
abuse and the opioid medications methadone and bupre-
norphine. Alteration in the CYP450 system is the basis
of most of the interactions between these substances.
Specifically, the nonnucleoside reverse transcriptase inhib-
itors (NNRTIs) and protease inhibitors (PIs), which form
the backbone of highly active antiretroviral therapy, are all
metabolized by (ie, are substrates of) the CYP450 enzymes,
most by CYP3A4. In addition, each of the NNRTIs and PIs
induce and/or inhibit specific CYP450 enzymes. Among
the NNRTIs, efavirenz and nevirapine induce CYP3A4,
while delavirdine inhibits CYP3A4, and etravirine induces
CYP3A4 while inhibiting CYP2C9 and CYP2C19. In vitro
studies show most of the PIs are CYP3A4 inhibitors
(atazanavir, darunavir/ritonavir, lopinavir/ritonavir, saqui-
navir, tipranavir/ritonavir), or strong CYP3A4 inhibitors
(indinavir/ritonavir, nelfinavir, ritonavir). Some PIs both
inhibit and induce CYP3A4 (amprenavir, fosamprenavir).
Ritonavir also inhibits CYP2D6. The nucleoside/nucleotide
reverse transcriptase inhibitors (NRTIs), the fusion inhibitor
enfuvirtide, and the integrase inhibitor raltegravir are not
metabolized by the CYP450 system.
It can be difficult to determine which mechanisms are
responsible for drug interactions. Although in vitro studies
reliably show induction or inhibition of specific CYP
enzymes, these do not predict drug interactions when the
compounds inhibit some and induce other enzymes, and do
not predict responses in humans who ingest these medica-
tions. In this article, we review research on pharmacokinetic
interactions of ARVs with street drugs, methadone, and
buprenorphine.
Street Drug Interactions with Antiretrovirals
Street drugs, or drugs of abuse, are drugs that are obtained
and often manufactured illegally, and taken for the
subjective effects they produce. They often contain impu-
rities and may cause unexpected toxicity. Fortunately, street
drugs do not significantly induce or inhibit the CYP450
enzymes that metabolize many ARVs. However, many street
drugs are substrates of one or more CYP450 enzymes, and
their effects may be decreased or increased by ARVs that
induce or inhibit these enzymes. Although there is almost no
research in this area, a number of interactions are likely given
their known metabolic pathways.
Heroin and Other Opiates
Commonly abused derivatives of the opium poppy include
heroin (metabolized by plasma esterases to morphine),
morphine (metabolized by glucuronidation), and codeine
(metabolized by glucuronidation). Although ARVs are also
metabolized by glucuronidation, no interactions between
them and heroin, morphine, and codeine have been reported.
Commonly abused semisynthetics include oxycodone and
hydrocodone, commonly prescribed for pain and widely
available on the street. Both are metabolized by CYP2D6,
and hydrocodone is also metabolized by CYP3A4 [5]. The
effects of oxycodone may be increased and decreased
when strong CYP2D6 inhibitors such as ritonavir are started
and stopped, respectively. Hydrocodone is metabolized by
CYP2D6 to a more potent metabolite, hydromorphone; as a
result, the CYP2D6 inhibitor ritonavir may decrease rather
than increase the effects of hydrocodone [5], resulting in
opiate withdrawal symptoms and requests for dose increases.
Cocaine
Cocaine is a known immunotoxic agent, decreasing CD4
production threefold and increasing HIV reproduction up to
20-fold [6]. Cocaine is metabolized by plasma and hepatic
esterases. However, about 10% is metabolized by CYP450
enzymes, including CYP3A4. Chronic cocaine administra-
tion has been shown to induce CYP3A4 in rodents [7].
If cocaine induces CYP3A4 in humans as well, it may
decrease levels and effectiveness of the many ARVs that are
CYP3A4 substrates, including most NNRTIs and PIs. P-
glycoprotein, an efflux transporter, is increased both by
HIV disease and chronic cocaine use [8]. For ARVs that are
transported by p-glycoprotein, such as abacavir [9]o r
indinavir [10], this may result in increased excretion, and
subtherapeutic ARV levels.
Ecstasy and Amphetamines
Amphetamines and ecstasy are primarily metabolized by
CYP2D6 [5]. Combining even a small dose of ecstasy with
the CYP2D6 inhibitor ritonavir has increased and pro-
longed the effects of ecstasy. In one report, a man died after
drinking beer and taking ecstasy after ritonavir was added
to his ARV regimen; he had had no adverse effects from
ecstasy previously [11]. Another case report [12] described
a near-fatal reaction (unresponsive, shallow respirations) in
a 29-year-old man who took his usual dose of ecstasy and
gamma-hydroxybutyrate (GHB) after having a change in
ARVs to saquinavir/ritonavir. This individual reported
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usual, and this effect continued for longer than when he had
taken similar doses of ecstasy before. A day later he took ½
teaspoonful of GHB to calm himself, similar to the quantity
he had taken as a sleep aid on many occasions without
adverse reactions. His friends were taking similar amounts
of the same preparation of GHB every 2 to 3 h without
adverse effects. Several hours later, he took another such
dose of GHB, but this time became unconscious. The
authors noted how drug users are often falsely reassured by
the reactions of other people they are using drugs with,
and recommended that clinicians caution patients that
interactions between street drugs and medications can be
unpredictable, sometimes dangerous, and differ widely
between individuals.
Gamma-Hydroxybutyrate
This depressant is believed to be metabolized by CYP2D6.
In combination with saquinavir/ritonavir, a CYP2D6
inhibitor, the combination of GHB and ecstasy has been
near-fatal [12].
Benzodiazepines
Several commonly abused benzodiazepines are metabolized
by CYP3A4. These include alprazolam (Xanax), clonazepam
(Klonopin),diazepam(Valium),andflunitrazepam(Rohypnol).
CYP3A4 inhibitors cause their levels to rise, resulting in
possible toxicities such as oversedation. For example, ritonavir
has been shown to decrease clearance and increase effects of
alprazolam [13]. Conversely, when CYP3A4 inhibitors are
stopped, patients may have benzodiazepine withdrawal
symptoms. Likewise, CYP3A4 inducers may cause with-
drawal symptoms and dose escalation (eg, medication
seeking) to avoid withdrawal.
Marijuana
The active ingredients of marijuana, THC and its metabo-
lites, are metabolized via CYP3A4 and to a lesser extent by
CYP2C9 [5]. Strong CYP3A4 inhibitors such as the PIs
indinavir, nelfinavir, and ritonavir may interfere with
marijuana metabolism and increase the risk of marijuana
toxicity, such as paranoia. Users can adjust to this by
smoking smaller amounts at a time to see how it affects
them. Fortunately, several studies showed no effects of
smoked marijuana on ARV metabolism [14, 15].
Dissociative Anesthetics
Although phencyclidine (PCP) is metabolized by CYP3A4,
and its derivative ketamine is metabolized by CYP3A4 and
CYP2B6, there are no reports of toxicity related to
CYP3A4 inhibitors [5].
LSD
LSD is metabolized by the liver, but little is known about
how this occurs. Patients should be advised about the
possibility of unknown interactions [5].
Summary
As described above, ritonavir, a CYP2D6 and CYP3A4
inhibitor, has been associated with life-threatening over-
doses from CYP2D6 substrates ecstasy and GHB, and has
been shown to increase blood levels and effects of the
benzodiazepine and CYP3A4 substrate alprazolam (Xanax).
For other street drugs, there is no published research on
interactions with ARVs, only knowledge of how they are
metabolized, and thus what interactions are likely. Street
drug toxicities might be expected with medications that
inhibit the enzymes metabolizing street drugs, such as
CYP2D6 (eg, ritonavir) for oxycodone, ecstasy, and GHB,
and CYP3A4 (eg, delavirdine, ritonavir, PIs) for marijuana,
certain benzodiazepines, PCP, and ketamine. Drug users
need to be advised that different people react differently to
street drugs, and that caution is needed after starting
medications that inhibit drug metabolism.
Methadone and Buprenorphine
Because adherence to medication regimens among people
with heroin addiction is often poor, effective treatment for
HIV in this population requires successful treatment for
opioid addiction, usually with opioid therapy. This can
prevent withdrawal symptoms and reduce craving that leads
opioid-addicted people to spend much of their time in
activities aimed at obtaining heroin or other opioids.
Interactions between methadone or buprenorphine and
other medications can result in suboptimal or excessive
levels of the opiate therapy or of the other medication.
Subtherapeutic levels of ARVs increase the risk of viral
resistance, viral replication, and treatment failure. Similarly,
inadequately treated opioid withdrawal symptoms are a
primary reason why patients resume illicit drug use and drop
out of opioid treatment. This increases risk of nonadherence,
development of viral resistance to ARVs, and of return to
unsafe drug use and sexual practices that spread HIV to
others [16]. Conversely, excessive concentrations of either
therapy may cause unwanted side effects leading to treatment
nonadherence, treatment discontinuation, or overdose.
Methadone, a long-acting μ-opioid receptor agonist, is
especially helpful with opioid-addicted patients who can
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structured treatment program. It is also the first choice for
heroin-addicted patients who have chronic pain needing to
be managed with opioid analgesics. In the United States,
methadonetreatmentforaddictionisallowedonlyinspecialty
methadone clinics that are regulated by the Substance Abuse
and Mental Health Services Administration (SAMHSA) [17].
Buprenorphine, a μ-opioid receptor partial agonist with
high affinity to opioid receptors, blocks other opioids’ access
tothe opioidreceptors. As such,atdoses used for treatment of
opioid dependence, buprenorphine can block the effect of a
fullμ-agonistanalgesic.BecausebuprenorphineisaSchedule
III drug, in the United States it is available by prescription
from physicians with a Drug Enforcement Administration
waiver that can be obtained with 8 h of SAMHSA-approved
training. Therefore, buprenorphine can be provided in any
medical setting, such as HIV primary care. This allows
patients with complex medical problems and opioid depen-
dence to be treated by the same physician [18].
Buprenorphine has fewer possible drug interactions than
methadone, for both pharmacokinetic and pharmacodynamic
reasons. Buprenorphine is absorbed sublingually, thus com-
peting less with ARVs for absorption in the gastrointestinal
(GI) tract. Methadone is metabolized via CYP 2B6 and
2C19, with mixed literature on the involvement of CYP 3A4,
and with minor 2C8 and 2D6 pathways [19, 20￿, 21￿].
Buprenorphine is primarily converted to an active metabo-
lite, norbuprenorphine, via CYP3A4 and to a lesser extent by
CYP2C8. Buprenorphine and its metabolite norbuprenor-
phine are further metabolized by glucuronidation, reducing
thepotentialofcompetingwithotherdrugsintheCYPsystem
and therefore reducing the likelihood of clinically significant
drug interactions when compared to methadone [22]. The
naloxone that buprenorphine is often formulated with to
discourage misuse is also metabolized by glucuronidation.
Neither methadone nor buprenorphine are major inducers
or inhibitors of P450 enzymes (methadone is a moderate
CYP2D6 inhibitor in vitro); however, they could compete
with other medications metabolized by these same pathways.
Pharmacodynamically, as a partial agonist, buprenor-
phine has a ceiling effect at higher concentrations. Thus,
when the metabolism of buprenorphine is inhibited, higher
concentrations do not produce typical opioid toxicity effects
such as respiratory depression [23]. On the other hand, when
buprenorphine metabolism is induced, its high affinity for
the μ-opioid receptors [18] may allow it to stay on the
receptors despite falling plasma concentrations.
Effects of ARVs on Methadone
Table 1 shows the interactions of ARVs with methadone and
buprenorphine. Most of the interactions are ARV effects on
methadone metabolism. Several NNRTIs strongly induce
CYP3A4 and have been shown to lower methadone plasma
concentrations and cause methadone withdrawal symptoms
such as anxiety, abdominal cramps, and muscle and joint pain.
The NNRTI efavirenz decreased methadone area under the
curved (AUC) 55% and required methadone dose increases on
average by 52% [24￿]. Similarly, when methadone mainte-
nance patients were started on the NNRTI nevirapine,
methadone AUC decreased by 63%, resulting in opioid
withdrawal among 9 of 10 patients, and requiring an average
20% increase in methadone dose [25￿￿].
The NNRTI etravirine induces CYP3A4 but inhibits
CYP2C19, another route of methadone metabolism. A study
of etravirine given over 14 days showed slightly increased
methadone AUC, and no need for methadone dose adjustment
[26￿].
For the NNRTIs known to induce methadone metabo-
lism, methadone dose increases are often needed. However,
an immediate methadone dose increase could result in
opioid toxicity since it cannot be predicted who will
develop opiate withdrawal or severity. Therefore, a dose
increase prior to onset of objective signs and symptoms of
opiate withdrawal is not recommended. Moreover, CYP
enzyme induction requires the synthesis of new enzymes,
generally over 7 to 21 days, which is therefore the time
frame for onset of opiate withdrawal and need for a
methadone dose increase. Because methadone providers
manage methadone dose in these patients, it is important for
HIV providers to let methadone treatment providers know
when a new ARV with inducing properties is initiated, so
that they can monitor for opioid withdrawal symptoms and
then adjust the methadone dose as needed.
Conversely, when inducers are stopped (such as when
primary providers decide to stop them, or when patients
decide to stop or decrease the medication on their own, or
when patients are unable to get a medication refilled due to
financial issues), methadone levels increase, resulting in
possible sedation, constipation, respiratory depression, cardi-
acarrhythmias,andothertoxicities.Whenmethadonepatients
receiving CYP3A4-inducing ARVs experience methadone
toxicity, this may be due to cessation of or nonadherence to
these ARVs. For example, efavirenz can cause dizziness,
somnolence, insomnia, or confusion. If patients decrease or
stop thismedicationtoavoid these side effects,theymay beat
risk for opioid toxicity. Methadone patients who have had
their dose increased to accommodate efavirenz or nevirapine
need to be monitored closely for possible methadone toxicity
in case they go off these medications unexpectedly.
Although in vitro studies indicate that the PIs inhibit
CYP3A4, many have been found to decrease rather than
increase methadone concentrations in humans, possibly due to
other metabolic processes such as renal clearance or induction
of other CYP enzymes. Several PIs are associated with reduced
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including darunavir/ritonavir [27] and lopinavir/ritonavir [28￿].
A case report described how a patient developed Torsades de
Pointes (cardiac arrhythmia reported in association with
methadone) after stopping lopinavir/ritonavir, due to failure
to reduce the methadone dose that had been increased when
lopinavir/ritonavir was started [29￿]. Nelfinavir decreased
methadone AUC, but no withdrawal was observed [30￿]. In
a study with healthy volunteers not on methadone mainte-
nance, nelfinavir decreased methadone plasma concentrations
40% despite 50% CYP3A4 inhibition, by increasing renal
clearance [20￿]. Similarly, ritonavir decreased methadone
concentrations despite CYP3A4 inhibition, also by increasing
renal clearance [31￿]. Tipranavir/ritonavir has been shown to
reduce methadone serum concentration 50% [32], despite
CYP3A4 inhibition. The mechanism may be its induction of
CYP2C19 and intestinal p-glycoprotein [33￿].
Fortunately, there are several PIs without significant
effects on methadone AUC, including the CYP3A4 inhibitors
atazanavir [34], indinavir/ritonavir [21￿], saquinavir/ritonavir
[35￿], and the mixed CYP3A4 inhibitor and inducer
fosamprenavir/ritonavir [36￿].
In sum, studies of methadone maintenance patients
starting efavirenz, nevirapine, and several PIs have evidenced
decreased methadone concentrations and withdrawal symp-
toms requiring methadone dose increases when these medi-
cations are started and methadone dose decreases when they
are stopped. For efavirenz and nevirapine, these drug
interactions are consistent with their induction of CYP3A4.
In contrast, for many PIs these drug interactions are opposite
to their inhibition of CYP3A4 and thus most likely due to
other mechanisms.
Effects of ARVs on Buprenorphine
To date, few of the effects of NNRTIs or PIs on methadone
metabolism have been observed with buprenorphine. For
Table 1 Interactions between antiretroviral medications, methadone, and buprenorphine
HIV medications Methadone Buprenorphine
NRTIs
Zidovudine Increase in zidovudine levels; possible zidovudine
toxicity [46￿]
No clinically significant interaction [47￿]
Didanosine Decrease in didanosine levels if in tablet form [43];
no change in enteric-coated form [44]
No change in didanosine levels [45]
Stavudine Decrease in stavudine levels [43] Not studied
NNRTIs
Delavirdine (3A4 inhibitor) Increased methadone levels but no opioid toxicity [48] Increased buprenorphine levels but
no opioid toxicity [37￿]
Efavirenz (3A4 inducer) Opioid withdrawal may occur [24￿] Decreased buprenorphine levels but
no withdrawal symptoms [37￿]
Etravirine (3A4 inducer, 2C19 inhibitor) Increased methadone levels but no opioid toxicity [26￿] Not studied
Nevirapine (3A4 and 2B6 inducer) Decreased methadone AUC, opioid withdrawal [25￿￿] No effect on buprenorphine levels,
no withdrawal symptoms [38￿]
PIs (CYP3A4 inhibitors unless specified otherwise)
Atazanavir No increase in methadone levels [34] Increases in buprenorphine levels;
cognitive dysfunction [41￿￿, 42]
Fosamprenavir (mixed 3A4 inducer
and inhibitor)
No significant change in methadone levels [36￿] Under study
Darunavir/ritonavir Opioid withdrawal may occur [27, 49] Under study
Indinavir/ritonavir (strong 3A4 inhibitor) No significant change in methadone levels [21￿] Not studied
Lopinavir/ritonavir Opioid withdrawal may occur [28￿, 29￿] No significant change in buprenorphine
levels or adverse events [39￿]
Nelfinavir (strong 3A4 inhibitor) Increased methadone renal clearance, decreased
methadone levels [20￿, 30￿]; opioid withdrawal
may occur [50]
Did not affect buprenorphine levels or
cause adverse events [39￿]
Ritonavir (strong 3A4 and 2D6 inhibitor) Increased methadone renal clearance [31￿] Increased buprenorphine levels, but not
adverse events [39￿]
Saquinavir/ritonavir No significant change in methadone levels [35￿] Not studied
Tipranavir/ritonavir (3A4 and 2D6
inhibitor, 2C19 inducer)
Reduced methadone levels [32] No significant change in buprenorphine
levels [40￿￿]
NNRTI—nonnucleoside reverse transcriptase inhibitor; NRTI—nucleoside/nucleotide reverse transcriptase inhibitor; PI—protease inhibitor
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CYP3A4 and have been linked to opiate withdrawal
symptoms in methadone-maintained patients [24￿, 25￿￿].
In contrast, when given to buprenorphine-maintained
individuals, these medications were not associated with
opioid withdrawal despite reductions in buprenorphine
plasma concentrations. One of these, efavirenz, decreased
buprenorphine AUC significantly, but this did not lead to
withdrawal symptoms [37￿]. Similarly, nevirapine did not
significantly affect buprenorphine pharmacokinetics or lead
to withdrawal symptoms [38￿]. Research is needed on
whether the CYP3A4 inducer etravirine decreases bupre-
norphine AUC or causes withdrawal symptoms.
Similarly, a number of PIs are unrelated to buprenor-
phine withdrawal or toxicity, also in contrast to findings
with methadone. Several PIs that decrease methadone
levels and cause methadone withdrawal have no clinically
significant effects on buprenorphine levels, including
lopinavir/ritonavir, nelfinavir [39￿], and tipranavir/ritonavir
[40￿￿]. Darunavir/ritonavir causes methadone withdrawal
and is currently being studied with buprenorphine. The PI
ritonavir increased buprenorphine AUC, but without opioid
toxicity [39￿].
In contrast, while the PI atazanavir did not increase
methadone levels or methadone toxicity [34], it was found
to increase buprenorphine AUC by 93%, and 3 of 10 patients
complained of drowsiness [41￿￿]. Likewise, in a case report,
starting atazanavir was associated with cognitive impairment
in a patient on buprenorphine [42]. Given these unexpected
findings, research is needed on how buprenorphine levels are
affected by other CYP3A4-inhibiting PIs that do not affect
methadone levels, such as amprenavir/ritonavir, indinavir/
ritonavir, and saquinavir/ritonavir.
In sum, in research to date, buprenorphine has fewer
interactions with ARVs than methadone. The only ARV
shown to significantly affect buprenorphine concentrations
is atazanavir, which is linked to increased buprenorphine AUC
and drowsiness. Research is needed on etravirine, amprenavir,
fosamprenavir, indinavir/ritonavir, and saquinavir/ritonavir.
For HIV-positive patients with opioid addiction, buprenor-
phine shouldbe stronglyconsideredasthetreatmentofchoice.
In some cases methadone is the treatment of choice (eg, with
chronic pain requiring treatment with opioid pain medications
that buprenorphine would block).
Effects of Methadone and Buprenorphine on ARVs
Methadone has been shown to interact with at least one
ARV by reducing its absorption from the GI tract. As a full
μ-opioid receptor agonist, methadone slows GI motility.
This increases degradation of medications that are sensitive
to the acidic environment of the stomach. This has been
observed when methadone-maintained patients were adminis-
teredtheNRTIstavudine,resultingin subtherapeutic stavudine
concentrations [43]. For the NRTI didanosine, AUC was
reduced by 63% when given in the early tablet form to
methadone-maintained individuals [43]. In contrast, the
newer enteric-coated capsule formulation of didanosine
designed to prevent degradation in the stomach remained at
therapeutic plasma levels in methadone-maintained individu-
als [44] and buprenorphine-maintained individuals [45].
Several ARVs are metabolized by glucuronidation.
Methadone inhibits glucuronidation of the NRTI zidovu-
dine and had been associated with zidovudine toxicity in
some cases; the symptoms of muscle and joint pain,
dysphoria, and insomnia of zidovudine toxicity can easily
be confused with opioid withdrawal symptoms [46￿]. This
increase in zidovudine levels was not found with bupre-
norphine [47￿]. Similarly, although the NNRTI nevirapine
is metabolized by glucuronidation, plasma levels are not
affected by buprenorphine [38￿]. Research is needed on
drug interactions that might occur with new ARVs
metabolized by glucuronidation, such as the integrase
inhibitor raltegravir.
Tipranavir/ritonavir plasma levels are lower in
buprenorphine-maintained patients than in historical controls
[40￿￿]. The mechanism for this interaction remains elusive.
In sum, methadone has been shown to lead to subther-
apeutic levels of the NRTI stavudine by decreasing its
absorption, and has been shown to inhibit glucuronidation
of the NRTI zidovudine resulting in toxicity that could be
confused with opioid withdrawal. Further research is
needed on how methadone and buprenorphine affect
glucuronidation of ARVs.
Conclusions
Many street drugs as well as ARVs are metabolized by
(substrates of) CYP450 enzymes (most often CYP3A4 or
CYP2D6). Fortunately, the currently available street drugs
are not known to significantly induce or inhibit the CYP450
enzymes. In contrast, many ARVs induce or inhibit
CYP3A4 and/or CYP2D6, and may thereby alter metabo-
lism of many street drugs. Although there is almost no
research in this area, toxicities and withdrawal symptoms
are likely when patients start or stop ARVs that inhibit
CYP3A4 or CYP2D6. Ritonavir, a CYP2D6 and CYP3A4
inhibitor, has been shown to increase blood levels and
effects of benzodiazepines metabolized by CYP3A4. Case
reports document life-threatening ecstasy and GHB toxicity
after starting ritonavir.
Methadone and buprenorphine are effective treatments
for opioid addiction. Because some ARVs decrease or
increase methadone levels, patients need to be monitored
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stop ARVs. Recent research shows that most ARVs do not
cause buprenorphine withdrawal or toxicity, even if they
affect buprenorphine levels. The one exception is the PI
combination atazanavir/ritonavir. Research is needed on a
number of other PIs that may have similar effects, such as
amprenavir, indinavir/ritonavir, and saquinavir/ritonavir.
Although buprenorphine has fewer drug–drug interactions
with ARVs than methadone, opioid-addicted patients who are
stable on methadone maintenance should not necessarily be
transferred to buprenorphine, because it can be clinically
challenging to reduce the methadone dose to a point where
transition tobuprenorphine ispossible. Rather, clinicians with
HIV-positive patients on methadone maintenance should be
aware of major drug interactions that may occur between
ARVs and methadone and adjust methadone doses as
clinically indicated. If a patient with HIV or at risk for HIV
is new to opioid therapy or wishes to be readmitted to opioid
therapy, buprenorphine may be preferable as it appears that it
will have fewer clinically significant interactions with ARVs.
The findings to date on how ARVs affect the metabolism
of street drugs, methadone, and buprenorphine, and how
methadone affects the metabolism of a number of ARVs,
are useful to clinicians who must treat both HIV disease
and opioid dependence in the same patients. However, at
this point it is not possible to predict who will experience a
drug–drug interaction, as this relates to individual genetics
thataffectmetabolism.Improvement inmedicationadherence
and clinical outcomes can be enhanced by discussion with
patients about possible interactions, clinical monitoring, and
rapid intervention should a drug–drug interaction occur.
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